Literature DB >> 11396186

Immunohistochemical reactivity of anti-melanoma monoclonal antibody 225.28S in human breast cancer biopsies.

L Dell'Erba1, G Calo-Gabrieli, M L Caruso, R Thomas, G Cortino, A M Valentini, P Muto, M Albrizio, M I Pastena, S Lastoria.   

Abstract

The high molecular weight melanoma-associated antigen, defined by murine monoclonal antibody (IgG1) 225.28S is largely expressed by melanoma cells and weakly expressed by other human tumors originating from neural crest. In this study, we analyzed the immunohistochemical reactivity of MoAb 225.28S in human breast cancer biopsies. A total of 92 breast cancer biopsies (66 infiltrating lobular and 26 infiltrating ductal carcinomas) were initially tested along with 26 melanomas (positive controls), 23 gastric/colonic adenocarcinomas and 13 neuroendocrine tumors. Forty-four out of 66 lobular breast carcinomas showed positive immunostaining with 225.28S MoAb as well as only 6 out of 26 infiltrating ductal histotype and 12 out of 26 melanomas. Conversely, gastric and colonic adenocarcinomas and neuroendocrine tumors were completely negative. The pattern of positivity in breast carcinomas was associated with malignant cells, rather than with the stroma or histiocytes infiltrating the lesions. Nonspecific cross-reactivity of 225.28S with breast carcinomas was excluded using a similar murine antithyreoglobulin MoAb, which gave negative staining in all biopsies. These results indicated that HMW-MAA or a similar sequence recognized by 225.28S MoAb is often expressed by lobular breast carcinomas but rarely by ductal adenocarcinomas. This seems to suggest that lobular breast carcinoma has common "ancestor" antigens with melanoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396186

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.

Authors:  Yuying Liu; Weihe Zhang; Lawrence H Cheung; Ting Niu; Qingping Wu; Chun Li; Carolyn S Van Pelt; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

2.  Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.

Authors:  Pål K Selbo; Michael G Rosenblum; Lawrence H Cheung; Wendy Zhang; Kristian Berg
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

Review 3.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.